About
Ousia, from the Greek for "essence"; Ousia Pharma emerged from a groundbreaking academic discovery at University of Copenhagen and rapidly evolved into a biotechnology company. We are pioneering innovative therapeutic strategies centered on peptide-drug conjugates to improve the lives of patients with cardiometabolic diseases.
Who are we?
Ousia Pharma ApS is a Danish biotech start-up focused on the development of novel peptide-drug conjugates for the treatment of metabolic diseases. We utilize a targeting approach in which peptides are used to deliver modulators of synaptic plasticity to appetite controlling regions of the brain.
The Team
Anders Bue Klein
Co-Founder, CEO, PhD in neuroscience Anders Bue Klein has a strong background in molecular metabolism and pharmocology with an impressive academic track record and has previously held an Assistant Professor position at the NNF Center for Basic Metabolic Research
Christoffer Clemmensen
Co-Founder, CSO, PhD in metabolism, Group Leader (Clemmensen Lab) Christoffer Clemmensen leads an academic laboratory at the NNF Center for Basic Metabolic Research and has held various international positions at highly ranked research institutions
Jonas O. Petersen
Co-Founder, COO, PhD in medicinal chemistry Besides his PhD in medicinal chemistry, Jonas O. Petersen holds a Master of Engineering in Advancend Chemistry
Board of Directors
Ian Laquian
Chairman of the Board, MSc, MBA, serial entrepreneur, Kariya, Lophora, Avilex
Christoffer Clemmensen
Co-Founder, CSO, PhD in metabolism, Group Leader (Clemmensen Lab) Christoffer Clemmensen leads an academic laboratory at the NNF Center for Basic Metabolic Research and has held various international positions at highly ranked research institutions
Otello Stampacchia
PhD in Molecular Biology (Geneva), MSc in Genetics (Pavia), serial investor (e.g. Omega Funds, Alpinvest, Lombard Odier, Goldman Sachs)
Menelas Pangalos
Former EVP R&D AstraZeneca, senior R&D roles at GSK & Wyeth, Fellow of the Royal Society, visiting prof (Kings, Manchester, Cambridge)
Elisabeth Björk
MD, PhD, endocrinologist, formerly SVP AstraZeneca RD
Mission
We are dedicated to developing effective and safe pharmacotherapies to improve the health and lives of people living with cardiometabolic disease.